Enhancement of Cognitive Function by Andrographolide-Loaded Lactose β-Cyclodextrin Nanoparticles: Synthesis, Optimization, and Behavioural Assessment
-
Published:2024-07-21
Issue:7
Volume:17
Page:966
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Paramanick Debashish1, Rani Kagithala Naga1, Singh Vijay Kumar2, Basist Parakh3, Khan Rahmuddin4ORCID, Al-Tamimi Jameel H.5, Noman Omar M.6ORCID, Ibrahim Mansour N.7, Alhalmi Abdulsalam4ORCID
Affiliation:
1. School of Medical and Allied Science, Galgotias University, Greater Noida 203201, India 2. School of Pharmacy, Rawatpura Sarkar University, Raipur 492015, India 3. School of Medical and Allied Sciences, K.R. Mangalam University, Gurugram 122103, India 4. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India 5. Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia 6. Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia 7. Department of Agricultural Engineering, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia
Abstract
This study investigates whether Andrographolide-loaded Lactose β-Cyclodextrin (ALN-βCD) nanoparticles enhance cognitive function, particularly spatial learning and memory. The successful conjugation of lactose to β-cyclodextrin was confirmed via 1H NMR spectroscopy, facilitating neuronal cell entry. The solvent evaporation method was used to create the nanoparticles, which were characterised for particle size, PDI, zeta potential, and drug release. The nanoparticles exhibited a size of 247.9 ± 3.2 nm, a PDI of 0.5 ± 0.02, and a zeta potential of 26.8 ± 2.5 mV. FTIR and TEM analyses, along with in vitro drug release and BBB permeability studies, confirmed their stability and efficacy. Behavioural tests, including the Elevated Plus Maze, Y-Maze, Object Recognition, and Locomotor Activity tests, demonstrated significant improvements in memory, motor coordination, and exploration time in the nanoparticle-treated groups. The group treated with ALN-βCD at a dose of 100 mg/kg/p.o. showed superior cognitive performance compared to the group receiving free andrographolides (AG). Biochemical assays indicated a significant reduction in acetylcholinesterase activity and lipid peroxidation, suggesting increased acetylcholine levels and reduced oxidative stress. Histopathological examination showed improved neuronal function without toxicity. The results showed significant improvements (p < 0.001) in memory and cognitive abilities in experimental animals, highlighting the potential of ALN-βCD nanoparticles as a non-invasive treatment for memory loss. These promising findings warrant further exploration through clinical trials.
Funder
King Saud University, Riyadh, Saudi Arabia
Reference43 articles.
1. Ayeni, E.A., Aldossary, A.M., Ayejoto, D.A., Gbadegesin, L.A., Alshehri, A.A., Alfassam, H.A., Afewerky, H.K., Almughem, F.A., Bello, S.M., and Tawfik, E.A. (2022). Neurodegenerative Diseases: Implications of Environmental and Climatic Influences on Neurotransmitters and Neuronal Hormones Activities. Int. J. Environ. Res. Public Health, 19. 2. Alzheimer’s Association (2020). 2020 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement., 16, 391–460. 3. Tamagno, E., Guglielmotto, M., Vasciaveo, V., and Tabaton, M. (2021). Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First: The Chicken or the Egg?. Antioxidants, 10. 4. Amyloid β-Based Therapy for Alzheimer’s Disease: Challenges, Successes and Future;Zhang;Signal Transduct. Target. Ther.,2023 5. Hassan, N.A., Alshamari, A.K., Hassan, A.A., Elharrif, M.G., Alhajri, A.M., Sattam, M., and Khattab, R.R. (2022). Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology. Molecules, 27.
|
|